ArticlePloS one2015
Alpha-synuclein levels in blood plasma decline with healthy aging.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Plasma alpha-synuclein predicts cognitive impairment in Parkinson's disease: a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- One-year longitudinal cohort study of chemosensory recovery and plasma biomarker dynamics in SARS-CoV-2 survivors.Scientific reports · 2026Article
- Targeting the Microbiota-Gut-Brain Axis: Bacillus coagulans Protects Against Rotenone-Induced Parkinson's Disease in Rats.Neurochemical research · 2026Article
- Challenging the paradigm of alpha-synuclein's role in disease: can low levels also be bad for you?Sleep · 2025Article
- Neuroprotective effect of Bacillus subtilis in haloperidol induced rat model, targeting the microbiota-gut-brain axis.Journal of molecular histology · 2024Article
- From inflammatory signaling to neuronal damage: Exploring NLR inflammasomes in ageing neurological disorders.Heliyon · 2024Review
- Pain-Free Alpha-Synuclein Detection by Low-Cost Hierarchical Nanowire Based Electrode.Nanomaterials (Basel, Switzerland) · 2024Article
- Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.Biomolecules · 2023Review
- AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies.NPJ Parkinson's disease · 2023Article
- Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?Frontiers in molecular neuroscience · 2023Review
- Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.NPJ Parkinson's disease · 2022Review
- Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson's disease.Animal cells and systems · 2021Article
- Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological α-Synuclein in Parkinson's Disease Patients.ACS chemical neuroscience · 2020Article
- Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.Neuroscience and biobehavioral reviews · 2019Review
- Mathematical Biology Models of Parkinson's Disease.CPT: pharmacometrics & systems pharmacology · 2019Review
- Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay.Frontiers in neuroscience · 2019Article
- Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging.Frontiers in aging neuroscience · 2019Article
- Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- α-Synuclein activates innate immunity but suppresses interferon-γ expression in murine astrocytes.The European journal of neuroscience · 2018Article
- α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise.Frontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is unequivocal evidence that alpha-synuclein plays a pivotal pathophysiological role in neurodegenerative diseases, and in particular in synucleinopathies. These disorders present with a variable extent of cognitive impairment and alpha-synuclein is being explored as a biomarker in CSF, blood serum and plasma. Considering key events of aging that include proteostasis, alpha-synuclein may not only be useful as a marker for differential diagnosis but also for aging per se. To explore this hypothesis, we developed a highly specific ELISA to measure alpha-synuclein. In healthy males plasma alpha-synuclein levels correlated strongly with age, revealing much lower concentrations in older (avg. 58.1 years) compared to younger (avg. 27.6 years) individuals. This difference between the age groups was enhanced after acidification of the plasmas (p<0.0001), possibly reflecting a decrease of alpha-synuclein-antibody complexes or chaperone activity in older individuals. Our results support the concept that alpha-synuclein homeostasis may be impaired early on, possibly due to disturbance of the proteostasis network, a key component of healthy aging. Thus, alpha-synuclein may be a novel biomarker of aging, a factor that should be considered when analyzing its presence in biological specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.